Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its long-awaited non-opioid ...
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...